Bevacizumab (Avastin) for metastatic pancreatic cancer

Homepage

Search the NeLM

Medicines A-Z

Find key information about medicines by name (prototype)

Browse by Categories:

Browse by NeLM area:

Bevacizumab (Avastin) for metastatic pancreatic cancer

Reference: National Horizon Scanning Centre (NHSC), New and Emerging Technology Briefing, September 2007

Source: NHSC

Date published: 14/02/2008 00:00

Summary

by: Anonymous

A New and Emerging Technology Briefing from the National Horizon Scanning Centre on the use of bevacizumab (Avastin®) for metastatic pancreatic cancer.

About this library entry

Category: 8.1.5 Other antineoplastic drugs | Cancer: pancreas | Drug reviews | Licence extension

NeLM area: Evidence > Drug Specific Reviews

Link

Preview your comment

Add new comment

Comment text:

Comments

There are no comments yet. You could be the first! You must be Logged In to comment.

Printer Friendly Version

Related evidence

8.1.5 Other antineoplastic drugs

09/02/2012

London Cancer New Drugs Group Rapid Review: Cabazitaxel for the second-line treatment of hormone-refractory metastatic prostate cancer

09/02/2012

London Cancer New Drugs Group Rapid Review: Everolimus for advanced pancreatic neuroendocrine tumours (pNET)

09/02/2012

London Cancer New Drugs Group Rapid Review: Erlotinib for the third or fourth-line treatment of NSCLC

Cancer: pancreas

07/02/2012

London Cancer New Drugs Group Rapid Review: Folfirinox for first line treatment of advanced pancreatic cancer

13/10/2011

AWMSG issues Final Appraisal Recommendation on sunitinib (Sutent®) for pancreatic neuroendocrine tumours

09/05/2011

SMC accepts use of sunitinib (Sutent®) for treatment of pancreatic neuroendocrine tumours within NHS Scotland

Back